Summary
Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson's Disease
MIAMI, FL / ACCESSWIRE / December 23, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the "Company", an emerging leader in age-reversal science, today announced significant findings from its copper binding studies with Telomir-1. This is a promising development as the company explores Telomir-1 for the treatment of Wilson's disease and other copper related disorders.
Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price
Transaction follows a $5 million non-dilutive credit line from the same trusted partner, further reinforcing Telomir's financial strength and growth potential. MIAMI, FL / ACCESSWIRE / December 12, 2024 / Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) ("Telomir" or the "Company"), an emerging leader in age-reversal science, today announced it has raised $1 million in equity funding through The Starwood Trust.
Why Is Telomir Pharmaceuticals Stock Trading Higher On Tuesday?
On Tuesday, Telomir Pharmaceuticals, Inc. TELO revealed preclinical results confirming the efficacy of its licensed molecule Telomir-1 in reversing several key parameters of Type 2 diabetes mellitus.
Telomir Pharmaceuticals Inc. (TELO) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Telomir Pharmaceuticals Inc. ever had a stock split?
Telomir Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Erez Aminov CEO | NASDAQ (CM) Exchange | 87975F104 CUSIP |
| US Country | 1 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Telomir Pharmaceuticals, Inc. is a pioneering name in the biopharmaceutical industry, operating in the pre-clinical stage with a focus on crafting pharmaceutical solutions aimed at the reversal of oxidative stress, cellular protection, and the regulation of bodily mechanisms for health enhancement. Formerly known as Metallo Therapies Inc., the company underwent a name change in October 2022, signaling a refined focus towards its innovative approach in combating aging and disease progression through the modulation of metal ions. Incorporated in 2021 and based in Miami, Florida, Telomir Pharmaceuticals is on a mission to leverage the power of its groundbreaking research and development capabilities to bring forth novel treatments that promise to redefine health and longevity.
Products and Services
- Telomir 1
An oral small molecule metal ion regulator, Telomir 1 is the flagship product of Telomir Pharmaceuticals, Inc., crafted with the aim to significantly extend telomere caps, restore cellular balance, and combat oxidative stress—a primary driver of aging and various disease progressions. Telomir 1 operates by modulating essential metal ions such as iron and copper, thereby fortifying the body's defenses against age-related conditions and diseases. The promise of Telomir 1 extends across a broad spectrum of conditions, including:
- Progeria: A rare genetic disorder that precipitates rapid aging in children, where Telomir 1 seeks to offer a groundbreaking approach to manage and potentially reverse the progression of this condition.
- Wilson's Disease: By managing toxic copper buildup in the body, Telomir 1 could provide a novel treatment avenue for this genetic disorder, offering hope to those affected.
- Age-related Macular Degeneration (AMD): As a leading cause of vision loss, AMD could be effectively managed with Telomir 1, showcasing the product’s versatility in addressing different facets of aging.
- Type 2 Diabetes, Cancer, and Alzheimer's Disease: The broad applicability of Telomir 1 also encompasses these common age-related diseases, highlighting its potential in significantly impacting healthcare outcomes and quality of life for a vast population segment.
Contact Information
